Market Intelligence, Clinical Progress, and High-Purity Reagents for Growth Disorders, Endocrine and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GHR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GHR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed by MS. |
View GHR Products |
| Gene Delivery | GHR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Cell-based assays preserve native membrane conformation. |
View GHR Products |
| Benchmark Ab | Anti-GHR Neutralizing Antibody (including Pegvisomant Biosimilar Sequence) Recombinant positive control for blocking assays. Endotoxin Controlled. |
View GHR Products |
| Validator | GHR siRNA Set For knockdown verification and assay specificity checks. |
View GHR Products |
| Natural Ligand | GH1 (Growth Hormone 1) Reference agonist for competitive binding assays and receptor activation positive control. |
View GH1 Products |
| Downstream Signaling (Biomarker) | IGF1 Downstream effector of GHR activation; primary biomarker for efficacy. |
View IGF1 Products |
| Downstream Receptor | IGF1R Downstream pathway validation for IGF1 signaling axis; combination and resistance studies. |
View IGF1R Products |
| Signaling Node | JAK2 Crucial kinase mediating GHR intracellular signaling; for direct interaction and inhibition experiments. |
View JAK2 Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Dimerization & Binding Kinetics | HEK293 Expressed (Native Glycosylation) ECD proteins preserve dimer interface; theoretical MW confirmed by MS for accurate SPR/BLI data. |
| In Vitro Cellular Signaling (JAK/STAT) | Sequence Verified Lentivirus for stable cell line generation; GHR antagonist mutant proteins (e.g., G120R) included as reference controls. |
| Lack of Validated Positive Controls | Recombinant Benchmark Antibodies (including Pegvisomant biosimilar sequence) and reference proteins (GHR ECD-Fc, GH1) provided. |
| False Positives in Endocrine Screening | Validated siRNA included for specificity checks; endotoxin controlled (<1 EU/μg). |
| Cross-species Toxicology (Cyno/Mouse) | Human/Mouse/Cyno GHR ortholog proteins available (>95% purity, sequence verified) for preclinical safety evaluation. |
| Selectivity vs Related Cytokine Receptors (PRLR, EpoR, IL6R) | Homolog panel strictly verified by mass spec for off-target liability screening. |
| Functional Antagonism Validation | Antagonist mutant proteins (G120R) included as reference controls; HTRF/AlphaLISA dimerization disruption assays supported. |
| Internalization / ADC Development | Full-length GHR lentivirus for stable cell lines; pHrodo-labeled antibody internalization assay kit available. |
Live GHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GHR-targeted therapeutics is heavily bifurcated into agonists for Growth Hormone Deficiency (GHD) and antagonists for Acromegaly. Major players such as Novo Nordisk (Somapacitan), Ascendis Pharma (Lonapegsomatropin), and Pfizer/OPKO (Somatrogon) have successfully shifted focus from daily injections to long-acting subcutaneous formulations. Beyond classical GH replacement, the next wave of R&D is targeting ultra-long-acting profiles, oral delivery, and precise receptor modulation. For antagonist development, pegvisomant (Somavert) remains the only approved GHR antagonist, but emerging modalities include monoclonal antibodies (e.g., from biotech pipelines) and antisense oligonucleotides (ASO) such as IONIS-GHR-LRx from Ionis Pharmaceuticals for tissue-specific GHR downregulation. ASO approaches account for an estimated 45% of the GHR-targeted pipeline, followed by monoclonal antibodies (~35%), ADC (~15%), and small molecule allosteric modulators (~5%). Future directions include combination therapies with IGF1R inhibitors for oncology, GLP-1RAs for metabolic disease, and CNP for skeletal dysplasias. Tissue-specific delivery (e.g., GalNAc-ASO for liver) and next-generation long-acting technologies (Fc-fusion, albumin-binding) are expected to dominate the next 3-5 years.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting Agonist | Novo Nordisk, Ascendis Pharma | Growth Hormone Deficiency (Pediatric/Adult) | Receptor binding kinetics (Need high-purity GHR ECD-Fc for SPR/BLI affinity ranking) |
| Recombinant Protein Antagonist | Pfizer (Somavert) | Acromegaly | Receptor binding inhibition (Need high-purity ECD-Fc and dimerization blockade assay) |
| Monoclonal Antagonist/Nanobody | Emerging Biotech / Academic | Acromegaly, Cancer Cachexia | Neutralization assay and dimerization inhibition (Need full-length GHR lentivirus for cell-based assay) |
| Antisense Oligonucleotide (ASO) | Ionis, Tersus Pharmaceuticals | Acromegaly, Metabolic Disease | Target engagement validation (Need high-purity GHR ECD-Fc for binding confirmation and cross-species orthologs) |
| Antibody-Drug Conjugate (ADC) | Preclinical Stage | Solid Tumors (GHR+) | Internalization assay (Need full-length GHR lentivirus for stable cell lines and pHrodo internalization kit) |
| Small Molecule / Allosteric Modulator | Early Discovery | Metabolic, NASH | Binding assay with ECD and differential scanning fluorimetry (DSF) for allosteric binding detection |